SLC44A2 expression is positively correlated with the infiltration levels of B cells, CD4+ T cells, CD8+ T cells, Neutrophils, Macrophages, and Dendritic cells within CRC tumors (Fig. S6A), implying that SLC44A2 may enhance the effectiveness of immunotherapy in CRC. The gene discussed is CD4; the disease is colorectal carcinoma.